Rep. April McClain Delaney Sells Off IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares

Key Points

• Representative April McClain Delaney sold shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) valued between $1,001 and $15,000 on July 9th, as disclosed in a filing on August 5th.
• IDEXX Laboratories reported a $3.63 EPS for the latest quarter, surpassing analysts' expectations of $3.28, with a revenue of $1.11 billion, marking a 10.6% increase year-over-year.
• Several analysts have rated IDEXX Laboratories with a consensus rating of "Moderate Buy" and a target price averaging $623.56.

Representative April McClain Delaney (D-Maryland) recently sold shares of IDEXX Laboratories, Inc. NASDAQ: IDXX. In a filing disclosed on August 05th, the Representative disclosed that they had sold between $1,001 and $15,000 in IDEXX Laboratories stock on July 9th.

Representative April McClain Delaney also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Entegris NASDAQ: ENTG on 7/28/2025.
• Purchased $1,001 - $15,000 in shares of Brown & Brown NYSE: BRO on 7/25/2025.
• Purchased $1,001 - $15,000 in shares of Markel Group NYSE: MKL on 7/25/2025.
• Purchased $1,001 - $15,000 in shares of PTC NASDAQ: PTC on 7/11/2025.
• Sold $1,001 - $15,000 in shares of Entegris NASDAQ: ENTG on 7/9/2025.
• Purchased $1,001 - $15,000 in shares of Markel Group NYSE: MKL on 7/9/2025.
• Purchased $1,001 - $15,000 in shares of CDW NASDAQ: CDW on 7/9/2025.
• Sold $1,001 - $15,000 in shares of STERIS NYSE: STE on 6/26/2025.
• Purchased $1,001 - $15,000 in shares of Paychex NASDAQ: PAYX on 6/26/2025.
• Sold $1,001 - $15,000 in shares of Clean Harbors NYSE: CLH on 6/20/2025.

IDEXX Laboratories Stock Down 2.8%

IDXX stock opened at $624.19 on Thursday. The company has a market cap of $50.20 billion, a price-to-earnings ratio of 51.97, a price-to-earnings-growth ratio of 4.32 and a beta of 1.49. The company has a fifty day moving average price of $539.63 and a 200 day moving average price of $476.14. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.81. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $688.12.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported $3.63 EPS for the quarter, beating analysts' consensus estimates of $3.28 by $0.35. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The business had revenue of $1.11 billion during the quarter, compared to analysts' expectations of $1.06 billion. During the same period in the prior year, the company earned $2.44 earnings per share. The business's revenue was up 10.6% compared to the same quarter last year. Sell-side analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have weighed in on IDXX shares. Jefferies Financial Group started coverage on IDEXX Laboratories in a research report on Tuesday, July 1st. They set a "buy" rating and a $625.00 price objective for the company. Morgan Stanley set a $722.00 price objective on shares of IDEXX Laboratories and gave the company an "overweight" rating in a research report on Tuesday. Stifel Nicolaus set a $640.00 target price on shares of IDEXX Laboratories in a research note on Monday. JPMorgan Chase & Co. raised their price objective on shares of IDEXX Laboratories from $550.00 to $675.00 and gave the company an "overweight" rating in a research report on Monday. Finally, Leerink Partners raised their price target on IDEXX Laboratories from $580.00 to $600.00 and gave the company an "outperform" rating in a report on Thursday, July 17th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, IDEXX Laboratories presently has a consensus rating of "Moderate Buy" and a consensus target price of $623.56.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director M Anne Szostak sold 1,260 shares of the stock in a transaction on Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total transaction of $645,548.40. Following the sale, the director owned 1,801 shares of the company's stock, valued at $922,724.34. This trade represents a 41.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.98% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On IDEXX Laboratories

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IDXX. Vanguard Group Inc. grew its position in shares of IDEXX Laboratories by 1.5% in the first quarter. Vanguard Group Inc. now owns 9,855,937 shares of the company's stock valued at $4,139,001,000 after purchasing an additional 146,427 shares during the last quarter. Bamco Inc. NY lifted its stake in IDEXX Laboratories by 4.3% in the 4th quarter. Bamco Inc. NY now owns 2,005,522 shares of the company's stock valued at $829,163,000 after buying an additional 82,264 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in IDEXX Laboratories by 71.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,988,912 shares of the company's stock valued at $835,244,000 after buying an additional 825,965 shares during the last quarter. Bank of New York Mellon Corp increased its position in IDEXX Laboratories by 156.2% during the second quarter. Bank of New York Mellon Corp now owns 1,451,390 shares of the company's stock worth $778,439,000 after buying an additional 884,808 shares in the last quarter. Finally, Invesco Ltd. increased its position in IDEXX Laboratories by 0.5% during the first quarter. Invesco Ltd. now owns 1,166,406 shares of the company's stock worth $489,832,000 after buying an additional 5,418 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland's 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027. McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland's 6th Congressional District. She declared candidacy for the 2026 election. April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor's degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.